Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01353209 · ClinicalTrials.gov registry record · Phase 2
Letrozole for Lymphangioleiomyomatosis
A Phase 2 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT01353209 is a Phase 2 study that has completed, run by University of Cincinnati. The registered enrollment target is 17 participants.
The verdict
NCT01353209, a Phase 2 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
The hypothesis in this study is that estrogen suppression by an aromatase inhibitor in postmenopausal women with lymphangioleiomyomatosis (LAM) will prevent or delay progression of lung disease and result in a decrease in the rate of decline in FEV1
Interventions
- DRUG Placebo
- DRUG Letrozole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2011-05 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01353209
The ClinicalTrials.gov registry entry for NCT01353209 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01353209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01353209 about?
NCT01353209 is a clinical study titled "Letrozole for Lymphangioleiomyomatosis". The hypothesis in this study is that estrogen suppression by an aromatase inhibitor in postmenopausal women with lymphangioleiomyomatosis (LAM) will prevent or delay progression of lung disease and result in a decrease in the rate of decline in FEV1
What is the current status of trial NCT01353209?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2011-05. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01353209?
The interventions under investigation include: Placebo (DRUG), Letrozole (DRUG).
Who is sponsoring clinical trial NCT01353209?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.